CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
bevacizumab and CPT-11 and Carboplatindrug
Likely dose
bevacizumab and CPT-11 and Carboplatin 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00953121
NCT00953121Phase 2Completed
CompareCT.gov

Phase II Study of Bevacizumab Plus Irinotecan and Carboplatin for Recurrent Malignant Glioma Patients

Annick Desjardins·interventional·Posted Aug 6, 2009·Updated Sep 16, 2013

In Brief

A Phase 2 clinical trial evaluating bevacizumab and CPT-11 and Carboplatin for Malignant Glioma. Completed, enrolled 104 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2009
Enrollment StartSep 1, 2009
Primary CompletionJul 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.9 years ago

Interventions

bevacizumab and CPT-11 and Carboplatindrug

Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.